Colospan

Colospan is a medical device company developing novel solutions for colorectal surgery to prevent anastomotic leaks and reduce the need for diverting stomas.

Health Tech & Life Sciences
Acquired by Eocene Ltd. (formerly Galmed Pharmaceuticals Ltd.)
Acquired Kfar Saba, Israel Founded 2010
Last updated 2026-11-10
Total raised
$22.3M
Last: Grant 2021-12
Stage
Acquired
Founded
2010
Headcount
11
HQ
Kfar Saba, Israel
Sector
Health Tech & Life Sciences

About

Colospan is a clinical-stage medical device company focused on developing proprietary technology for colorectal surgery. Its flagship product, CG-100, is a temporary intraluminal bypass device designed to protect colorectal anastomoses and reduce the need for diverting stomas. The company aims to improve clinical outcomes, simplify recovery, and reduce complications for patients undergoing colorectal surgery. Colospan's CG-100 is CE-marked in the EU and Israel, has received FDA Breakthrough Device Designation, and is approved for investigational use in the US.

Funding history · 6 rounds · $22.3M total

6 events/rounds · $22.3M Total Funding: $10.5M in Private Equity

Offices

Kfar Saba, Israel · HQ / main office

Q&A

What is Colospan's primary focus?
Colospan is a clinical-stage medical device company that develops proprietary technology for colorectal surgery, specifically focusing on preventing anastomotic leaks and reducing the need for diverting stomas.
What is Colospan's flagship product?
Colospan's flagship product is CG-100, a temporary intraluminal bypass device designed to protect colorectal anastomoses.
What is the regulatory status of Colospan's CG-100 device?
The CG-100 device is CE-marked in the EU and Israel, has received FDA Breakthrough Device Designation, and is approved for investigational use in the US.
When was Colospan acquired and by which company?
Colospan was acquired in June 2026 by Eocene Ltd. (formerly Galmed Pharmaceuticals Ltd.) for $4,500,000.
How much funding has Colospan raised in total?
Colospan has raised a total of $22,304,857 in funding.
When did Colospan receive its most recent grant funding?
Colospan received a grant of $9,300,000 in December 2021 from the European Innovation Council (EIC).
Which investors participated in Colospan's A Round funding?
In September 2015, Colospan raised $2,000,000 in an A Round, with VI Ventures as a lead investor.

Team · 7

Boaz Assaf
Founder · Founder & CEO
Eyal Teichman
Founder · CTO
Emilia Ozer
VP Quality
Shelly Sharon
VP Clinical Affairs EMEA
Orit Tal
VP Regulatory Affairs
Gregory D. Casciaro
Board Member
Michal Geva
Board Member

Sectors & technology

Primary sector
Health Tech & Life Sciences
Target customers
Business model
B2B

Highlights

Patents

Tags

gastroenterologysurgerymedical-devicessurgical-instrumentssurgeonspreventiontreatmentscancercolonoscopyhospitals
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

External links

Websitecolospan.com/
LinkedInlinkedin.com/company/68366723

Identifiers & details

Legal nameColospan Ltd.
Founded2010-12
Employees (exact)11

Acquisitions & public offerings

Acquired by Eocene Ltd. (formerly Galmed Pharmaceuticals Ltd.) 2026-06 $4.5M

Radar intelligence

Patents

EPO4

Web history (Wayback)

Domaincolospan.com

Certificate / subdomain footprint

Subdomains2

Israeli Companies Registrar (רשם החברות / ICA)

Registrar # (ח.פ.)514525971
Statusפעילה
Corp typeישראלית חברה פרטית
Incorporated2010-11-28
Purposeלעסוק בכל עיסוק חוקי
Liabilityמוגבלת
In violation (unfiled)no
Last annual report2026
Active charges / liens0
Registry events2 — annual_report (1), people (1)
Registered addressעתירי ידע 21 כפר סבא

Recent registry events

DateEvent
2026-02-10דו~ח שנתי
2026-02-08עדכון בעלי תפקידים